Evidence map›Paper›PMID 39807188›Full record

ArticleRSC advances2025

5-(3-(

Nanjia Cairang, Yanran Wu, Shumeng Zhi, Jiaqin Tang, Xin Tie, Dui Zhan, Guangyuan Lu, Ying Shi, Qipeng Zhao

Abstract read
In one paragraph

Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Drug Design for Cerebral Ischemia: A Molecular Perspective Review.CNS & neurological disorders drug targets · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nanjia CairangDepartment of Tibetan Medicine, University of Xizang Medicine 10 Dangre Middle Road, Chengguan District Lhasa City 850000 China xzzyxycn@163.com.
Yanran WuKey Laboratory of Protection, Development and Utilization of Medicinal Resources in Liupanshan Area (Ningxia Medical University), Ministry of Education, School of Pharmacy, Ningxia Medical University 1160 Shengli Street Yinchuan 750004 China nxshiying@163.com 25136659@qq.com.
Shumeng ZhiKey Laboratory of Protection, Development and Utilization of Medicinal Resources in Liupanshan Area (Ningxia Medical University), Ministry of Education, School of Pharmacy, Ningxia Medical University 1160 Shengli Street Yinchuan 750004 China nxshiying@163.com 25136659@qq.com.
Jiaqin TangKey Laboratory of Protection, Development and Utilization of Medicinal Resources in Liupanshan Area (Ningxia Medical University), Ministry of Education, School of Pharmacy, Ningxia Medical University 1160 Shengli Street Yinchuan 750004 China nxshiying@163.com 25136659@qq.com.
Xin TieKey Laboratory of Protection, Development and Utilization of Medicinal Resources in Liupanshan Area (Ningxia Medical University), Ministry of Education, School of Pharmacy, Ningxia Medical University 1160 Shengli Street Yinchuan 750004 China nxshiying@163.com 25136659@qq.com.
Dui ZhanDepartment of Tibetan Medicine, University of Xizang Medicine 10 Dangre Middle Road, Chengguan District Lhasa City 850000 China xzzyxycn@163.com.
Guangyuan LuNingxia Key Laboratory of Craniocerebral Diseases, Incubation Base of National Key Laboratory, Ningxia Medical University 1160 Shengli Street Yinchuan 750004 China lugy@nxmu.edu.cn.
Ying ShiKey Laboratory of Protection, Development and Utilization of Medicinal Resources in Liupanshan Area (Ningxia Medical University), Ministry of Education, School of Pharmacy, Ningxia Medical University 1160 Shengli Street Yinchuan 750004 China nxshiying@163.com 25136659@qq.com.ORCID https://orcid.org/0000-0002-9430-6152
Qipeng ZhaoKey Laboratory of Protection, Development and Utilization of Medicinal Resources in Liupanshan Area (Ningxia Medical University), Ministry of Education, School of Pharmacy, Ningxia Medical University 1160 Shengli Street Yinchuan 750004 China nxshiying@163.com 25136659@qq.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Keap1 (Kelch-like ECH-Associating Protein 1)-Nrf2 (Nuclear Factor Erythroid 2-Related Factor 2)-ARE (Antioxidant Response Element) signaling pathway plays a crucial role in the oxidative stress response and has been linked to the development and progression of various diseases. Its influence on cerebral ischemia/reperfusion (I/R) injury has garnered significant attention. In our study, we investigated the effect of compound 2, a non-covalent inhibitor of the Keap1-Nrf2 interaction, which was previously discovered by our research group. Specifically, we used 5-(3-(

Identifiers

PMID39807188
PMCPMC11726444

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.